Arbevel
16
20M
14
4
0.12
1
- Areas of investment
Summary
The venture was found in Europe in France. The leading representative office of defined Corporate Investor is situated in the Paris.
We can highlight the next thriving fund investment areas, such as Pharmaceutical, Therapeutics. For fund there is a match between the location of its establishment and the land of its numerous investments - France. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight TransCure bioServices, NH TherAguix.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Arbevel, startups are often financed by Venture Kick, EASME - EU Executive Agency for SMEs. The meaningful sponsors for the fund in investment in the same round are Supernova Invest, Omnes Capital, Bpifrance.
The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 5 - 10 millions dollars. The high activity for fund was in 2019.
Investments analytics
Analytics
- Total investments
- 16
- Lead investments
- 4
- Exits
- 1
- Follow on index
- 0.12
- Investments by industry
- Health Care (8)
- Medical (7)
- Biotechnology (4)
- Medical Device (3)
- E-Commerce (2) Show 20 more
- Investments by region
-
- France (13)
- United States (1)
- Israel (1)
- Switzerland (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 84K
- Group Appearance index
- 0.81
- Avg. company exit year
- 10
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Scipio Bioscience | 25 Feb 2020 | Biotechnology, Biopharma, Clinical Trials | Early Stage Venture | 7M | Ile-de-France, Paris, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.